NASDAQ:LEGN Legend Biotech Q3 2026 Earnings Date & Estimates $22.30 -0.23 (-1.02%) Closing price 04:00 PM EasternExtended Trading$22.04 -0.27 (-1.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Legend Biotech is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Legend Biotech in Q3 2026Legend Biotech is expected to post earnings of $0.01 per share on revenue of $361.46 million. In the same quarter a year earlier Legend Biotech reported -$0.11 per share on revenue of $272.33 million. Legend Biotech last reported on August 11, 2026, posting $0.09 per share and beating the $0.07 consensus estimate. Legend Biotech has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.01Expected Revenue$361.46 millionPrior-Year EPS-$0.11Prior-Year Revenue$272.33 millionExpected Revenue Growth+32.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.09 (Beat by +$0.02)Last Quarter Revenue$387.50 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Legend Biotech Q3 2026 Earnings FAQ When does Legend Biotech report Q3 2026 earnings? Legend Biotech (NASDAQ:LEGN) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Legend Biotech's Q3 2026 earnings call? Legend Biotech's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Legend Biotech? Analysts expect Legend Biotech to post earnings of $0.01 per share for Q3 2026. How much revenue is Legend Biotech expected to report? The consensus revenue estimate for Legend Biotech is $361.46 million for Q3 2026. Legend Biotech Earnings HeadlinesLegend Biotech (LEGN) Stock Could Trade Below Its Sales BackdropOctober 28 at 7:20 AM | finance.yahoo.comLegend Biotech to Host Investor Conference Call on Third Quarter 2026 ResultsOctober 27 at 8:00 AM | globenewswire.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 29 at 1:00 AM | Brownstone Research (Ad)Legend Biotech: Carvykti Makes Billions, But The Profits Are ElusiveOctober 22, 2026 | seekingalpha.comHC Wainwright Forecasts Stronger Earnings for Legend BiotechOctober 18, 2026 | americanbankingnews.comLegend Biotech Wins FDA IND Clearance for First Dual-Target In Vivo CAR-T LB2501October 17, 2026 | theglobeandmail.comSee More Legend Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Legend Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Legend Biotech and other key companies, straight to your email. Email Address About Legend BiotechLegend Biotech (NASDAQ:LEGN) Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells. Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. The product was developed through a global collaboration with Janssen Biotech, part of Johnson & Johnson, and has received regulatory approvals in multiple markets. Legend is also advancing additional cell-therapy candidates targeting hematologic malignancies and other potential applications. Founded in 2014, Legend Biotech operates internationally, with research, development and manufacturing activities supporting the development and supply of its therapies in major pharmaceutical markets. The company is headquartered in Somerset, New Jersey, and is led by Chief Executive Officer Ying Huang.View Legend Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
